WillItSurvive
Pharma and healthcare groups · United States

Johnson & Johnson

jnj.com ↗

Maker of prescription drugs and medical devices sold to hospitals and physicians worldwide.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from 2027 · Every call on the record Checkpoint: DePuy Synthes orthopaedics spin-off targeted completion
The call

J&J keeps growing past patent cliffs by spreading risk across 28 billion-dollar products, while talc litigation and the DePuy spin-off remain open questions.

Johnson & Johnson sells prescription medicines, vaccines, and medical devices to hospitals and doctors worldwide. It is difficult for competitors to copy because the company has government approvals that take years to get, long-standing relationships with hospitals and doctors, and many different drugs so it is not hurt badly when one loses patent protection to cheaper copies. The biggest risk right now is thousands of lawsuits over talc products that could cost billions of dollars and damage the company's reputation, though it currently makes enough money to handle this damage.

Why
01
AI pressure: None apparent. AI drug-discovery tools speed up J&J's own pipeline work more than they threaten its regulated drug and device sales. Could AI do the core job? Unlikely.
02
Bigger players: Biosimilar makers (Amgen, Samsung Bioepis, others) on Stelara and future Darzalex exposure. Stelara sales fell about 60% after biosimilars launched, and Darzalex faces a similar cliff ahead. Could a giant copy it? No, they are blocked.
03
What protects it. FDA-approved drug and device portfolios, deep hospital and physician distribution ties, and 28 separate billion-dollar products spreading out patent-cliff risk.
What would change this call
DePuy Synthes spin-off completes or stalls by mid-2027 target date. Shows whether J&J can execute separation without value loss or delay.
A talc verdict or settlement exceeds the ~$10B reserved range. Would indicate litigation risk outgrowing balance-sheet absorption capacity.
Darzalex sales growth slows as biosimilar filings or approvals emerge. Tests whether J&J's next big drug faces the same cliff as Stelara.
Key numbers
  • FY2025 revenue $94.19B, net income $26.80B (2025-12-31)
  • Stelara sales down ~59.7% in Q1 2026 (2026-01-30)
  • Market cap ~$594.6-627.6B (2026-07-15)
Named risks
  • Open-ended talc litigation with 68,435 pending cases and no comprehensive settlement as of July 2026. Severity: high
  • Patent cliffs across Stelara, Opsumit, Simponi and eventual Darzalex biosimilar exposure. Severity: high
  • DePuy Synthes spin-off execution risk during 18-24 month separation process announced Oct 2025. Severity: medium
  • Stock fell 2-3% on July 15, 2026 despite earnings beat, showing market sensitivity to litigation overhang. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Pfizergaining onJ&J's diversified 28 $1B+ brands vs Pfizer's concentrated LOE risk, per May 2026 analysis
AbbViecontestingBoth navigating overlapping $300B industry patent-cliff pressure as of Jan 2026
Merck & Co.contestingShared exposure to pharma patent-cliff wave through 2026-2030
Intuitive SurgicalcontestingJ&J's OTTAVA robotic surgery system advancing toward FDA authorization as of July 2026
MedtroniccontestingCompetes across MedTech segments including electrophysiology and orthopaedics
Questions people ask
Is Johnson & Johnson profitable in 2026?
Yes. J&J reported FY2025 revenue of $94.19B and net income of $26.80B. Q2 2026 sales hit $25.31B, up 6.6% reported, with adjusted EPS of $2.90 beating consensus. The company raised 2026 guidance and is on track to top $100B in annual revenue for the first time in its 140-year history (2026-07-15).
Who is Johnson & Johnson's biggest competitor?
Pfizer is the most-cited head-to-head rival given overlapping oncology and immunology franchises; analysts contrasted J&J's 28 diversified $1B+ brands against Pfizer's concentrated exposure to Eliquis, Ibrance and Xtandi patent expirations as of May 2026. Merck, AbbVie, Medtronic, Abbott and Intuitive Surgical are also named peers.
Could AI replace Johnson & Johnson's drug development?
No. J&J's own CIO Jim Swanson said in April 2026 that AI is not yet capable of discovering and bringing products to market outright. J&J uses AI to halve lead-optimization time and cut trial report prep from 700-900 hours, but FDA trials, manufacturing and liability remain human-run and regulator-gated.
Who owns Johnson & Johnson?
J&J is publicly traded on the NYSE under ticker JNJ with no controlling parent, and market cap sat around $594.6-627.6B as of mid-July 2026. It is one of only two US companies, alongside Microsoft, holding an AAA credit rating from S&P.
How big is Johnson & Johnson's talc litigation risk?
As of July 2026, roughly 68,435 talc-related cases remained pending in the MDL after J&J's third bankruptcy attempt (Red River Talc) was dismissed by a federal judge in March 2025. A $45M Illinois mesothelioma verdict was affirmed on appeal July 10, 2026, with no comprehensive settlement in place.
Is Stelara's decline hurting Johnson & Johnson?
Stelara, once J&J's top immunology drug at $9.7B in 2024, fell about 59.7% in Q1 2026 due to biosimilar competition, ending 2025 just over $6B, per a January 2026 PharmaVoice report. J&J offset this with double-digit growth excluding Stelara in Q2 2026, per its own July 15, 2026 earnings release.
Timeline
  • 2026-07-16DePuy Synthes acquires spine-implant firm Expanding Innovations
  • 2026-07-15Q2 2026 results: $25.31B sales, raised 2026 guidance toward $100B revenue
  • 2026-07-10Illinois appellate court affirms $45M talc mesothelioma verdict
  • 2026-06-30CFO named for DePuy Synthes ahead of planned J&J split
  • 2026-04-27CIO Jim Swanson says AI has halved drug-development lead-generation time
  • 2026-01-30Report: Stelara sales fall ~59.7% in Q1 2026 on biosimilar erosion
  • 2025-10J&J announces plan to separate DePuy Synthes orthopaedics business
  • 2025-09FDA approves Inlexzo bladder-cancer drug-delivery system
  • 2025-04-02J&J closes $14.6B acquisition of Intra-Cellular Therapies
  • 2025-03Federal judge dismisses J&J's third talc bankruptcy attempt (Red River Talc)
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources